The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science
- PMID: 36335802
- PMCID: PMC9641002
- DOI: 10.1016/j.neo.2022.100846
The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science
Abstract
Pediatric brain tumors are the leading cause of cancer-related death in children in the United States and contribute a disproportionate number of potential years of life lost compared to adult cancers. Moreover, survivors frequently suffer long-term side effects, including secondary cancers. The Children's Brain Tumor Network (CBTN) is a multi-institutional international clinical research consortium created to advance therapeutic development through the collection and rapid distribution of biospecimens and data via open-science research platforms for real-time access and use by the global research community. The CBTN's 32 member institutions utilize a shared regulatory governance architecture at the Children's Hospital of Philadelphia to accelerate and maximize the use of biospecimens and data. As of August 2022, CBTN has enrolled over 4700 subjects, over 1500 parents, and collected over 65,000 biospecimen aliquots for research. Additionally, over 80 preclinical models have been developed from collected tumors. Multi-omic data for over 1000 tumors and germline material are currently available with data generation for > 5000 samples underway. To our knowledge, CBTN provides the largest open-access pediatric brain tumor multi-omic dataset annotated with longitudinal clinical and outcome data, imaging, associated biospecimens, child-parent genomic pedigrees, and in vivo and in vitro preclinical models. Empowered by NIH-supported platforms such as the Kids First Data Resource and the Childhood Cancer Data Initiative, the CBTN continues to expand the resources needed for scientists to accelerate translational impact for improved outcomes and quality of life for children with brain and spinal cord tumors.
Keywords: Biospecimens; Collaborative international research infrastructure; Longitudinal clinical data; Molecular clinical trials; Multi-omic data; Pediatric brain tumors.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. David S. Ziegler is a consultant, or on the advisory board, of Bayer, AstraZeneca, Accendatech, Novartis, Day One, FivePhusion, Amgen, Alexion, and Norgine. Angela J. Waanders is on the advisory board of Alexion and Day One.
Figures
References
-
- Curtin SC, Minino AM, Anderson RN. Declines in Cancer Death Rates Among Children and Adolescents in the United States, 1999-2014. NCHS Data Brief. 2016;(257):1–8. - PubMed
-
- Pediatric brain tumor atlas [Internet]. [cited 2022 Oct 2]. Available from: https://cbtn.org/pediatric-brain-tumor-atlas
-
- Gabriella miller kids first [Internet]. 2021 [cited 2022 Oct 2]. Available from: https://commonfund.nih.gov/kidsfirst/2021X01projects
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
